

School of Public Health & Preventive Medicine

SEMINAR

Monday 17 August 1.30-2.30 pm

AMREP Seminar Room

Alfred Hospital Precinct, Melbourne 3004



Professor Paul Ridker, MD,
Harvard Medical School,
Director, Centre for Cardiovascular Disease
Prevention
Brigham and Women's Hospital

**“Inflammation, hsCRP, Statins, and
Primary Prevention: Controversies and
Implications of the JUPITER Trial”**

How do you identify those at risk from stroke who don't have high levels of cholesterol? And, once identified, what's the case for primary prevention - should they take medication to prevent a probable stroke event? Nearly 1.7 million heart attacks and strokes occur annually in the United States, and more than half of these occur among apparently healthy men and women with average or low levels of cholesterol. In a collaborative effort involving 1,315 physicians in 26 countries, the JUPITER (Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein) Study sought to determine whether statin therapy might be effective at preventing first-ever cardiovascular events in this class of patient.

Men and women at risk for vascular disease due to elevated levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) but who were not candidates for statin therapy under accepted guidelines were randomised to receive Rosuvastatin or placebo. The study was stopped after a median follow-up of 1.9 years as all pre-specified subgroups within JUPITER significantly benefitted from rosuvastatin. The study outcomes and implications are discussed in this talk.

All welcome, no RSVP required.

Enquiries to Dr John Varigos email John.Varigos@med.monash.edu.au ph 0411726848

<http://www.med.monash.edu.au/epidemiology/events/>